ReviewKidney diseases (Basel, Switzerland)2020
Acute Kidney Injury in the 2019 Novel Coronavirus Disease.
Review in Kidney diseases (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Organokines in COVID-19: A Systematic Review.Cells · 2023Pooled it
- Toxicity of psychotropic drugs in patients with COVID-19: A systematic review.General hospital psychiatryPooled it
- Acute Kidney Injury in the Context of COVID-19: An Analysis in Hospitalized Mexican Patients.Infectious disease reports · 2024Article
- Trajectory of AKI and hospital mortality among patients with COVID-19.Renal failure · 2023Article
- Lithium Therapy in COVID-19 with Bipolar Affective Disorder-A Case Series.Indian journal of psychological medicine · 2023Article
- Article
- Identification of the regulatory mechanism of ACE2 in COVID-19-induced kidney damage with systems genetics approach.Journal of molecular medicine (Berlin, Germany) · 2023Article
- Development of a Risk Score for AKI onset in COVID-19 Patients: COV-AKI Score.BMC nephrology · 2023Observational
- Altered kidney function induced by SARS-CoV-2 infection and acute kidney damage markers predict survival outcomes of COVID-19 patients: a prospective pilot study.Renal failure · 2022Article
- Regenerative therapy by using mesenchymal stem cells-derived exosomes in COVID-19 treatment. The potential role and underlying mechanisms.Regenerative therapy · 2022Review
- Renal consequences of the novel coronavirus disease 2019 (COVID-19) and hydrogen sulfide as a potential therapy.Nitric oxide : biology and chemistry · 2022Review
- COVID-19 pandemic and the widening oral health inequality in Nigeria.The Pan African medical journal · 2022Article
- Role of ACE2-Ang (1-7)-Mas axis in post-COVID-19 complications and its dietary modulation.Molecular and cellular biochemistry · 2022Review
- Human Organoids as a Promising Platform for Fighting COVID-19.International journal of biological sciences · 2022Review
- Are mesenchymal stem cells able to manage cytokine storm in COVID-19 patients? A review of recent studies.Regenerative therapy · 2021Review
- Jeopardy of COVID-19: Rechecking the Perks of Phytotherapeutic Interventions.Molecules (Basel, Switzerland) · 2021Review
- Acute kidney injury in COVID-19: multicentre prospective analysis of registry data.Clinical kidney journal · 2021Article
- Prospective selected biomarkers in COVID-19 diagnosis and treatment.Biomarkers in medicine · 2021Article
- The lethal internal face of the coronaviruses: Kidney tropism of the SARS, MERS, and COVID19 viruses.IUBMB life · 2021Review
- A descriptive and validation study of a predictive model of severity of SARS-COV-2 infection.Advances in laboratory medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe 2019 novel coronavirus disease (CO-VID-19) is a newly defined serious infectious disease caused by the SARS-CoV-2 virus. The epidemic started in Wuhan, China, in December of 2019 and quickly spread to over 200 countries. It has affected 4,258,666 people, with 294,190 deaths worldwide by May 15, 2020. COVID-19 is characterized by acute respiratory disease, with 80% of patients presenting mild like flu-like symptoms; however, 20% of patients may have a severe or critical clinical presentation, which likely causes multiple organ injuries (e.g., kidney, heart, blood, and nervous system). Among them, acute kidney injury (AKI) is a critical complication due to its high incidence and mortality rate. Here we present a review of the current understanding of AKI in COVID-19. SUMMARY: CO-VID-19 is a catastrophic contagious disease caused by the coronavirus, and the AKI induced by COVID-19 significantly increases the mortality rate. In this review, we summarize the clinical characteristics of COVID-19 induced AKI by focusing on its epidemiology, pathogenesis, clinical diagnosis, and treatment. KEY MESSAGES: Multiple studies have shown that COVID-19 may involve the kidneys and cause AKI. This article reviews the characteristics of COVID-19-induced AKI largely based on up-to-date studies in the hope that it will be helpful in the current global fight against and treatment of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.